Adagio Therapeutics Names David Hering Permanent CEO >ADGI

Dow Jones2022-07-05
 

By Colin Kellaher

 

Adagio Therapeutics Inc. on Tuesday said it named David Hering chief executive, removing the interim tag he has carried since February.

Mr. Hering stepped in at the helm of the Waltham, Mass., clinical-stage biopharmaceutical company after Tillman Gerngross resigned.

Adagio said Mr. Hering, who joined the company as chief operating officer in June 2021, will also serve on the board.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

$(END)$ Dow Jones Newswires

July 05, 2022 07:39 ET (11:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment